| Year |
Citation |
Score |
| 2022 |
Zeng W, Chu TTW, Chow EYK, Hu M, Fok BSP, Chan JCN, Yan BPY, Tomlinson B. Factors Associated with Aspirin Resistance in Hong Kong Chinese Patients with Stable Coronary Heart Disease Using the Multiplate Analyzer and Serum Thromboxane B. Pharmaceutics. 14. PMID 36297534 DOI: 10.3390/pharmaceutics14102099 |
0.385 |
|
| 2022 |
Zeng W, Hu M, Lee HK, Wat E, Lau CBS, Ho CS, Wong CK, Tomlinson B. Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T > C Polymorphism. Frontiers in Nutrition. 9: 868126. PMID 35685887 DOI: 10.3389/fnut.2022.868126 |
0.431 |
|
| 2022 |
Zeng W, Hu M, Lee HK, Wat E, Lau CBS, Ho CS, Wong CK, Tomlinson B. Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers. Frontiers in Nutrition. 9: 850318. PMID 35399656 DOI: 10.3389/fnut.2022.850318 |
0.419 |
|
| 2021 |
Tam CHT, Lim CKP, Luk AOY, Ng ACW, Lee HM, Jiang G, Lau ESH, Fan B, Wan R, Kong APS, Tam WH, Ozaki R, Chow EYK, Lee KF, Siu SC, ... ... Hu M, et al. Development of genome-wide polygenic risk scores for lipid traits and clinical applications for dyslipidemia, subclinical atherosclerosis, and diabetes cardiovascular complications among East Asians. Genome Medicine. 13: 29. PMID 33608049 DOI: 10.1186/s13073-021-00831-z |
0.375 |
|
| 2019 |
Hagger MS, Hamilton K, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF. Predicting intention to participate in self-management behaviors in patients with Familial Hypercholesterolemia: A cross-national study. Social Science & Medicine (1982). 242: 112591. PMID 31630009 DOI: 10.1016/J.Socscimed.2019.112591 |
0.46 |
|
| 2019 |
Pang J, Chan DC, Hu M, Muir LA, Kwok S, Charng MJ, Florkowski CM, George PM, Lin J, Loi DD, Marais AD, Nawawi HM, Gonzalez-Santos LE, Su TC, Truong TH, et al. Comparative aspects of the care of familial hypercholesterolemia in the "Ten Countries Study". Journal of Clinical Lipidology. PMID 30797720 DOI: 10.1016/J.Jacl.2019.01.009 |
0.416 |
|
| 2019 |
Tomlinson B, Hu M, Chow E. Current status of familial hypercholesterolemia in Chinese populations. Current Opinion in Lipidology. PMID 30649024 DOI: 10.1097/Mol.0000000000000580 |
0.456 |
|
| 2018 |
Hagger MS, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF. Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. Atherosclerosis. 277: 493-501. PMID 30270090 DOI: 10.1016/J.Atherosclerosis.2018.06.010 |
0.449 |
|
| 2018 |
Hagger MS, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF. Health literacy in familial hypercholesterolemia: A cross-national study. European Journal of Preventive Cardiology. 2047487318766954. PMID 29592531 DOI: 10.1177/2047487318766954 |
0.432 |
|
| 2017 |
Tomlinson B, Hu M, Chan J, Mcintyre A, Hegele R. Severe familial hypercholesterolaemia in two brothers with three heterozygous coding mutations in LDLR. Atherosclerosis. 263: e230. PMID 29365890 DOI: 10.1016/J.Atherosclerosis.2017.06.749 |
0.409 |
|
| 2017 |
Tomlinson B, Hu M, Chan J, Mcintyre A, Hegele R. Severe hypertriglycerideamia related to a novel mutation in TRIB1 and a known variant in APOA5. Atherosclerosis. 263: e230. PMID 29365889 DOI: 10.1016/J.Atherosclerosis.2017.06.748 |
0.417 |
|
| 2017 |
Pang J, Hu M, Lin J, Miida T, Nawawi HM, Park JE, Wu X, Ramli AS, Kim NT, Kwok S, Gonzalez-Santos LE, Su TC, Truong TH, Soran H, Yamashita S, et al. An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the "Ten Countries Study". Bmj Open. 7: e017817. PMID 29074516 DOI: 10.1136/Bmjopen-2017-017817 |
0.407 |
|
| 2017 |
Griffith JF, Hu M, Yeung DKW, Guo P, Lam SL, Xiao F, Wang D, Tomlinson B. Achilles Tendon Xanthomas: Fat-Water Separation at Baseline and After Treatment. Radiology. 161435. PMID 28825891 DOI: 10.1148/Radiol.2017161435 |
0.444 |
|
| 2017 |
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Evolocumab for the treatment of hypercholesterolemia. Expert Opinion On Biological Therapy. 1-15. PMID 28812389 DOI: 10.1080/14712598.2017.1365134 |
0.526 |
|
| 2017 |
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Alirocumab for the treatment of hypercholesterolaemia. Expert Opinion On Biological Therapy. PMID 28277798 DOI: 10.1080/14712598.2017.1305354 |
0.52 |
|
| 2017 |
Zhang K, Ding Y, Zhu M, Hu M, Wang S, Xiao Y. Calculating vibrational mode contributions to sound absorption in excitable gas mixtures by decomposing multi-relaxation absorption spectroscopy Applied Acoustics. 116: 195-204. DOI: 10.1016/j.apacoust.2016.09.025 |
0.417 |
|
| 2016 |
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Liraglutide for weight management: benefits and risks. Current Medical Research and Opinion. 1-9. PMID 27936966 DOI: 10.1080/03007995.2016.1271315 |
0.406 |
|
| 2016 |
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opinion On Drug Metabolism & Toxicology. PMID 27817207 DOI: 10.1080/17425255.2017.1258401 |
0.477 |
|
| 2016 |
Zeng W, Chu T, Hu M, Kong A, Tomlinson B. OS 31-02 ANTIHYPERTENSIVE RESPONSE TO BISOPROLOL WAS NOT RELATED TO POLYMORPHISMS IN ADRB1 Or CYP2D6 IN CHINESE HYPERTENSIVE PATIENTS. Journal of Hypertension. 34: e388. PMID 27754210 DOI: 10.1097/01.hjh.0000500990.24186.18 |
0.422 |
|
| 2016 |
Hu M, Lee HK, To KK, Fok BS, Wo SK, Ho CS, Wong CK, Zuo Z, Chan TY, Chan JC, Tomlinson B. Telmisartan increases systemic exposure to rosuvastatin after single and multiple doses, and in vitro studies show telmisartan inhibits ABCG2-mediated transport of rosuvastatin. European Journal of Clinical Pharmacology. PMID 27651239 DOI: 10.1007/S00228-016-2130-1 |
0.455 |
|
| 2016 |
Zeng W, Chu T, Hu M, Kong A, Tomlinson B. OS 31-02 ANTIHYPERTENSIVE RESPONSE TO BISOPROLOL WAS NOT RELATED TO POLYMORPHISMS IN ADRB1 Or CYP2D6 IN CHINESE HYPERTENSIVE PATIENTS. Journal of Hypertension. 34: e388. PMID 27643167 DOI: 10.1097/01.Hjh.0000500990.24186.18 |
0.49 |
|
| 2016 |
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opinion On Drug Metabolism & Toxicology. PMID 27607315 DOI: 10.1080/17425255.2016.1234608 |
0.456 |
|
| 2016 |
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion On Investigational Drugs. 1-13. PMID 27563838 DOI: 10.1080/13543784.2016.1221925 |
0.424 |
|
| 2016 |
Chan SW, Xiao Y, Hu M, Yin OQ, Chu TT, Fok BS, Lee VH, Tomlinson B. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. Journal of Clinical Pharmacy and Therapeutics. PMID 27511886 DOI: 10.1111/Jcpt.12433 |
0.584 |
|
| 2016 |
Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of Fenugreek on Hyperglycaemia and Hyperlipidemia in Diabetes and Prediabetes: a Meta-analysis. Journal of Ethnopharmacology. PMID 27496582 DOI: 10.1016/j.jep.2016.08.003 |
0.405 |
|
| 2016 |
Watts GF, Ding PY, George P, Hagger MS, Hu M, Lin J, Khoo KL, Marais AD, Miida T, Nawawi HM, Pang J, Park JE, Gonzalez-Santos LB, Su TC, Truong TH, et al. Translational Research for Improving the Care of Familial Hypercholesterolemia: The "Ten Countries Study" and Beyond. Journal of Atherosclerosis and Thrombosis. PMID 27384016 DOI: 10.5551/Jat.35949 |
0.455 |
|
| 2016 |
Tomlinson B, Hu M, Zhang Y, Liu ZM, Chan P. Response to the letter "No evidence to support high-intensity statin in Chinese patients with coronary heart disease". International Journal of Cardiology. 209: 192-193. PMID 26896621 DOI: 10.1016/J.Ijcard.2016.02.047 |
0.433 |
|
| 2016 |
Hu M, Hooper AJ, Bockxmeer FM, Watts GF, Chan JC, Tomlinson B. Management of Familial Hypercholesterolemia in Hong Kong. Journal of Atherosclerosis and Thrombosis. PMID 26875521 DOI: 10.5551/Jat.34314 |
0.523 |
|
| 2016 |
Wang J, Gan X, Zhao H, Hu M, Li K, Qin W, Qiu G. Dissolution and passivation mechanisms of chalcopyrite during bioleaching: DFT calculation, XPS and electrochemistry analysis Minerals Engineering. 98: 264-278. DOI: 10.1016/j.mineng.2016.09.008 |
0.395 |
|
| 2016 |
Yan W, Hu M, Liang J, Wang D, Wei Y, Zhang W, Qin Y. Preparation and room temperature NO2-sensing performances of n-porous silicon/n-WO3 nanowires heterojunction Materials Research Bulletin. 83: 453-458. DOI: 10.1016/j.materresbull.2016.06.040 |
0.384 |
|
| 2016 |
Hu M, Tam C, So W, Chan J, Tomlinson B, Ma R. Genetic variants and lipid traits in the Hong Kong Chinese patients with type 2 diabetes Atherosclerosis. 252: e148. DOI: 10.1016/J.Atherosclerosis.2016.07.729 |
0.476 |
|
| 2016 |
Hu M, Chan J, Tomlinson B. Rare variants in ABCG2 identified by sequencing may influence the lipid response to rosuvastatin treatment Atherosclerosis. 252: e202-e203. DOI: 10.1016/J.Atherosclerosis.2016.07.125 |
0.397 |
|
| 2015 |
Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. An overview of novel GLP-1 receptor agonists for type II diabetes. Expert Opinion On Investigational Drugs. PMID 26587691 DOI: 10.1517/13543784.2016.1123249 |
0.45 |
|
| 2015 |
Hu M, Fok BS, Wo SK, Lee VH, Zuo Z, Tomlinson B. Effect of common polymorphisms of the farnesoid X receptor and bile acid transporters on the pharmacokinetics of ursodeoxycholic acid. Clinical and Experimental Pharmacology & Physiology. PMID 26382575 DOI: 10.1111/1440-1681.12490 |
0.496 |
|
| 2015 |
Ding C, Hu M, Wu YJ, Tomlinson B. Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia. Lipids in Health and Disease. 14: 107. PMID 26365713 DOI: 10.1186/S12944-015-0116-0 |
0.499 |
|
| 2015 |
Wang D, Shi L, Chu WC, Hu M, Tomlinson B, Huang WH, Wang T, Heng PA, Yeung DK, Ahuja AT. Fully automatic and nonparametric quantification of adipose tissue in fat-water separation MR imaging. Medical & Biological Engineering & Computing. PMID 26245254 DOI: 10.1007/S11517-015-1347-Y |
0.561 |
|
| 2015 |
Hu M, Yang YL, Chan P, Tomlinson B. Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia. Pharmacogenomics. 16: 1387-97. PMID 26226939 DOI: 10.2217/Pgs.15.79 |
0.478 |
|
| 2015 |
Hu M, Yang YL, Masuda D, Yamashita S, Tomlinson B. Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia. Disease Markers. 2015: 154014. PMID 26063948 DOI: 10.1155/2015/154014 |
0.44 |
|
| 2015 |
Hu M, Yang YL, Ng CF, Lee CP, Lee VW, Hanada H, Masuda D, Yamashita S, Tomlinson B. Effects of phenotypic and genotypic factors on the lipid responses to niacin in chinese patients with dyslipidemia. Medicine. 94: e881. PMID 25997070 DOI: 10.1097/Md.0000000000000881 |
0.536 |
|
| 2015 |
Liu ZM, Hu M, Chan P, Tomlinson B. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opinion On Investigational Drugs. 24: 611-21. PMID 25604802 DOI: 10.1517/13543784.2015.1006359 |
0.453 |
|
| 2015 |
Ding C, Hu M, Wu YJ, Tomlinson B. Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia Lipids in Health and Disease. 14. DOI: 10.1186/s12944-015-0116-0 |
0.421 |
|
| 2015 |
Hu M, Fok B, Wo S, Lee V, Zuo Z, Tomlinson B. Influence of farnesoid X receptor and bile acid transporter polymorphisms on the pharmacokinetics of ursodeoxycholic acid Atherosclerosis. 241: e118. DOI: 10.1016/J.Atherosclerosis.2015.04.411 |
0.442 |
|
| 2015 |
Hu M, Yang Y, Masuda D, Yamashita S, Tomlinson B. Is there a role for niacin in familial hypercholesterolaemia? Atherosclerosis. 241: e109. DOI: 10.1016/J.Atherosclerosis.2015.04.383 |
0.418 |
|
| 2014 |
Hu M, Tomlinson B. Niacin for reduction of cardiovascular risk. The New England Journal of Medicine. 371: 1941-2. PMID 25390751 DOI: 10.1056/Nejmc1411240#Sa3 |
0.415 |
|
| 2014 |
Xiao YJ, Hu M, Tomlinson B. Effects of grapefruit juice on cortisol metabolism in healthy male Chinese subjects. Food and Chemical Toxicology : An International Journal Published For the British Industrial Biological Research Association. 74: 85-90. PMID 25265455 DOI: 10.1016/J.Fct.2014.09.012 |
0.605 |
|
| 2014 |
To KK, Hu M, Tomlinson B. Expression and activity of ABCG2, but not ABCB1 or OATP1B1, are associated with cholesterol levels: evidence from in vitro and in vivo experiments. Pharmacogenomics. 15: 1091-104. PMID 25084202 DOI: 10.2217/Pgs.14.58 |
0.506 |
|
| 2014 |
Hu M, Yuen YP, Kwok JS, Griffith JF, Tomlinson B. Potential effects of NPC1L1 polymorphisms in protecting against clinical disease in a chinese family with sitosterolaemia. Journal of Atherosclerosis and Thrombosis. 21: 989-95. PMID 25056759 DOI: 10.5551/Jat.24679 |
0.506 |
|
| 2014 |
Hu M, Tomlinson B. Ezetimibe treatment should be considered for patients with sitosterolemia. Pediatric Nephrology (Berlin, Germany). 29: 1469-70. PMID 24839218 DOI: 10.1007/S00467-014-2843-2 |
0.441 |
|
| 2014 |
Hu M, Zeng W, Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evidence-Based Complementary and Alternative Medicine : Ecam. 2014: 365742. PMID 24834096 DOI: 10.1155/2014/365742 |
0.509 |
|
| 2014 |
Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opinion On Drug Metabolism & Toxicology. 10: 51-65. PMID 24156555 DOI: 10.1517/17425255.2014.851667 |
0.495 |
|
| 2014 |
Faiz F, Hu M, Hooper AJ, Tomlinson B, Van Bockxmeer FM. Molecular characterization of a Chinese woman homozygous for the familial hypercholesterolemia LDLR c.1474G>A (p.Asp492Asn) mutation Clinical Lipidology. 9: 163-170. DOI: 10.2217/Clp.14.6 |
0.475 |
|
| 2014 |
HU M, Yang Y, Yamashita S, Masuda D, Tomlinson B. Effect of niacin on oxidized low-density lipoprotein levels in Chinese patients with dyslipidaemia Atherosclerosis. 235: e256. DOI: 10.1016/J.Atherosclerosis.2014.05.766 |
0.479 |
|
| 2014 |
Hu M, Yang Y, Ng C, Lee C, Lee V, Tomlinson B. DGAT1 and DGAT2 polymorphisms had no effect on the lipid responses to niacin in Chinese patients with dyslipidaemia Atherosclerosis. 235: e256. DOI: 10.1016/J.Atherosclerosis.2014.05.765 |
0.525 |
|
| 2014 |
Zeng W, Hu M, Tomlinson B. Pharmacogenetics of antihypertensive therapies: Can this be applied in the clinic? Current Pharmacogenomics and Personalized Medicine. 12: 72-88. |
0.418 |
|
| 2013 |
Yang YL, Hu M, Chang M, Tomlinson B. A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. Journal of Clinical Pharmacy and Therapeutics. 38: 528-32. PMID 24020480 DOI: 10.1111/Jcpt.12096 |
0.395 |
|
| 2013 |
Hu M, Tomlinson B. Lipid-lowing pharmacogenomics in Chinese patients. Expert Review of Cardiovascular Therapy. 11: 985-97. PMID 23952137 DOI: 10.1586/14779072.2013.814839 |
0.483 |
|
| 2013 |
Lee HK, Hu M, Lui SSh, Ho CS, Wong CK, Tomlinson B. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 14: 1283-94. PMID 23930675 DOI: 10.2217/Pgs.13.115 |
0.522 |
|
| 2013 |
Hu M, Tomlinson B. Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics. 14: 981-95. PMID 23746191 DOI: 10.2217/Pgs.13.71 |
0.531 |
|
| 2013 |
Lee HK, Ho CS, Hu M, Tomlinson B, Wong CK. Development and validation of a sensitive method for simultaneous determination of rosuvastatin and N-desmethyl rosuvastatin in human plasma using liquid chromatography/negative electrospray ionization/tandem mass spectrometry. Biomedical Chromatography : Bmc. 27: 1369-74. PMID 23722358 DOI: 10.1002/Bmc.2944 |
0.344 |
|
| 2013 |
Hu M, Lui SS, Ko GT, Tomlinson B. Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. International Journal of Cardiology. 168: 3071-3. PMID 23642826 DOI: 10.1016/J.Ijcard.2013.04.091 |
0.501 |
|
| 2013 |
Hu M, Tomlinson B. Current Perspectives on rosuvastatin. Integrated Blood Pressure Control. 6: 15-25. PMID 23637557 DOI: 10.2147/IBPC.S34814 |
0.441 |
|
| 2013 |
Hu M, Mak VW, Xiao Y, Tomlinson B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics. 14: 25-34. PMID 23252946 DOI: 10.2217/Pgs.12.181 |
0.663 |
|
| 2013 |
Chan SW, Hu M, Ko SS, Tam CW, Fok BS, Yin OQ, Chow MS, Tomlinson B. CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. European Journal of Clinical Pharmacology. 69: 799-806. PMID 23090703 DOI: 10.1007/S00228-012-1428-X |
0.479 |
|
| 2013 |
Hu M, Mak VW, Yin OQ, Chu TT, Tomlinson B. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metabolism and Pharmacokinetics. 28: 104-8. PMID 22850760 DOI: 10.2133/Dmpk.Dmpk-12-Rg-067 |
0.496 |
|
| 2013 |
Hu M, Lan W, Lam CW, Mak YT, Pang CP, Tomlinson B. Heterozygous familial hypercholesterolemia in Hong Kong Chinese. Study of 252 cases. International Journal of Cardiology. 167: 762-7. PMID 22464486 DOI: 10.1016/J.Ijcard.2012.03.048 |
0.626 |
|
| 2013 |
Yang Y, Hu M, Tomlinson B. Lipid-modifying effects of nicotinic acid with laropiprant in Hong Kong Chinese patients with dyslipidaemia International Journal of Cardiology. 164: S16. DOI: 10.1016/S0167-5273(13)70569-2 |
0.398 |
|
| 2012 |
Hu M, Cheung BM, Tomlinson B. Safety of statins: an update. Therapeutic Advances in Drug Safety. 3: 133-44. PMID 25083232 DOI: 10.1177/2042098612439884 |
0.493 |
|
| 2012 |
Hu M, Mak VW, Tomlinson B. Polymorphisms in apolipoprotein E and apolipoprotein A-V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia. Journal of Clinical Lipidology. 6: 585-92. PMID 23312054 DOI: 10.1016/J.Jacl.2012.02.005 |
0.518 |
|
| 2012 |
Hu M, Fan L, Zhou HH, Tomlinson B. Theranostics meets traditional Chinese medicine: rational prediction of drug-herb interactions. Expert Review of Molecular Diagnostics. 12: 815-30. PMID 23249200 DOI: 10.1586/Erm.12.126 |
0.47 |
|
| 2012 |
Hu M, Mak VW, Tomlinson B. Comments on "CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women". Journal of Clinical Pharmacology. 52: 1768-9; author reply. PMID 23105125 DOI: 10.1177/0091270011415411 |
0.407 |
|
| 2012 |
Hu M, Tomlinson B. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia. Atherosclerosis. 223: 427-32. PMID 22749334 DOI: 10.1016/J.Atherosclerosis.2012.06.002 |
0.516 |
|
| 2012 |
Hu M, Yang YL, Fok BS, Chan SW, Chu TT, Poon EW, Yin OQ, Lee VH, Tomlinson B. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects. Drug Metabolism and Drug Interactions. 27: 33-9. PMID 22718623 DOI: 10.1515/Dmdi-2011-0032 |
0.5 |
|
| 2012 |
Hu M, Mak VW, Tomlinson B. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenetics and Genomics. 22: 803-6. PMID 22668755 DOI: 10.1097/Fpc.0B013E3283557C98 |
0.54 |
|
| 2012 |
Chan SW, Hu M, Tomlinson B. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure. Expert Opinion On Drug Metabolism & Toxicology. 8: 767-90. PMID 22621216 DOI: 10.1517/17425255.2012.685157 |
0.47 |
|
| 2012 |
Hu M, Lui SS, Tam LS, Li EK, Tomlinson B. The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin. Journal of Lipid Research. 53: 1384-9. PMID 22534644 DOI: 10.1194/Jlr.M026054 |
0.53 |
|
| 2012 |
Hu M, Chu WC, Yamashita S, Yeung DK, Shi L, Wang D, Masuda D, Yang Y, Tomlinson B. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. Journal of Lipid Research. 53: 802-9. PMID 22315393 DOI: 10.1194/Jlr.P023614 |
0.615 |
|
| 2012 |
Yin OQ, Mak VW, Hu M, Fok BS, Chow MS, Tomlinson B. Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects. European Journal of Clinical Pharmacology. 68: 943-9. PMID 22281720 DOI: 10.1007/S00228-011-1202-5 |
0.522 |
|
| 2012 |
Hu M, Wang DQ, Xiao YJ, Mak VW, Tomlinson B. Herb-drug interactions: methods to identify potential influence of genetic variations in genes encoding drug metabolizing enzymes and drug transporters. Current Pharmaceutical Biotechnology. 13: 1718-30. PMID 22039823 DOI: 10.2174/138920112800958805 |
0.669 |
|
| 2012 |
Lee VWY, Hu M, Tomlinson B. Integrating pharmacogenetics for assessment of herb-drug interactions: Has the time come? Current Pharmacogenomics and Personalized Medicine. 10: 247-253. DOI: 10.2174/187569212802509988 |
0.481 |
|
| 2012 |
Xiao Y, Chan SW, Hu M, Chu TTW, Fok BSP, Poon EWM, Tomlinson B. Simultaneous determination of cortisol, cortisone, and 6β- hydroxycortisol in human urine by UPLC with UV detector and application to determine diurnal variations Chromatographia. 75: 169-173. DOI: 10.1007/S10337-011-2162-8 |
0.584 |
|
| 2011 |
Yang Y, Chan SW, Hu M, Walden R, Tomlinson B. Effects of some common food constituents on cardiovascular disease. Isrn Cardiology. 2011: 397136. PMID 22347642 DOI: 10.5402/2011/397136 |
0.449 |
|
| 2011 |
Hu M, Mak VWL, Tomlinson B. Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition Journal of Clinical Pharmacy and Therapeutics. 36: 419-425. PMID 21545622 DOI: 10.1111/J.1365-2710.2010.01184.X |
0.419 |
|
| 2011 |
Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opinion On Drug Metabolism & Toxicology. 7: 49-62. PMID 21091277 DOI: 10.1517/17425255.2011.538383 |
0.493 |
|
| 2011 |
Hu M, Thomas GN, Tomlinson B. Lipid disorders in Chinese populations Clinical Lipidology. 6: 549-562. DOI: 10.2217/Clp.11.47 |
0.508 |
|
| 2011 |
Hu M, Mak V, Poon E, Tomlinson B. 110 ASSOCIATIONS OF APOE POLYMORPHISMS WITH BASELINE LIPIDS AND RESPONSE TO ROSUVASTATIN VARY IN CHINESE PATIENTS WITH AND WITHOUT FAMILIAL HYPERCHOLESTEROLAEMIA Atherosclerosis Supplements. 12: 26. DOI: 10.1016/S1567-5688(11)70111-8 |
0.461 |
|
| 2011 |
Yang Y, Hu M, Chan S, Fok B, Chu T, Lee V, Tomlinson B. P062 Flecainide Pharmacokinetics are Influenced by CYP3A5 and ABCB1 Polymorphisms International Journal of Cardiology. 147: S26. DOI: 10.1016/S0167-5273(11)70088-2 |
0.401 |
|
| 2010 |
Hu M, Lee MH, Mak VW, Tomlinson B. Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily). The American Journal of Cardiology. 106: 1588-93. PMID 21094359 DOI: 10.1016/J.Amjcard.2010.07.044 |
0.544 |
|
| 2010 |
Hu M, Tomlinson B. Growth hormone-releasing factor agonists for the treatment of HIV-associated lipodystrophy. Current Opinion in Investigational Drugs (London, England : 2000). 11: 1143-50. PMID 20872317 |
0.364 |
|
| 2010 |
Hu M, Tomlinson B. Pharmacokinetic evaluation of lanreotide. Expert Opinion On Drug Metabolism & Toxicology. 6: 1301-12. PMID 20716034 DOI: 10.1517/17425255.2010.513700 |
0.406 |
|
| 2010 |
Hu M, Lui SS, Mak VW, Chu TT, Lee VW, Poon EW, Tsui TK, Ko GT, Baum L, Tam LS, Li EK, Tomlinson B. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenetics and Genomics. 20: 634-7. PMID 20679960 DOI: 10.1097/Fpc.0B013E32833De489 |
0.535 |
|
| 2010 |
You JH, Chan WK, Chung PF, Hu M, Tomlinson B. Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects. Journal of Clinical Pharmacology. 50: 1151-8. PMID 20150526 DOI: 10.1177/0091270009358082 |
0.514 |
|
| 2010 |
Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clinical Pharmacology and Therapeutics. 87: 558-62. PMID 20130569 DOI: 10.1038/Clpt.2009.232 |
0.528 |
|
| 2010 |
Liu ZK, Hu M, Baum L, Thomas GN, Tomlinson B. Associations of polymorphisms in the apolipoprotein A1/C3/A4/A5 gene cluster with familial combined hyperlipidaemia in Hong Kong Chinese. Atherosclerosis. 208: 427-32. PMID 19732897 DOI: 10.1016/J.Atherosclerosis.2009.08.013 |
0.463 |
|
| 2009 |
Hu M, Mak V, Chu T, Waye M, Tomlinson B. Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease Current Pharmacogenomics and Personalized Medicine. 7: 1-26. DOI: 10.2174/187569209787582349 |
0.522 |
|
| 2009 |
Mak V, Hu M, Chu T, Poon E, Tsui T, Tomlinson B. Abstract: P487 EFFECTS OF COMMON SINGLE NUCLEOTIDE POLYMORPHISMS AND HAPLOTYPES OF SLCO1B1 IN CHINESE ON THE PLASMA LIPID RESPONSES TO SIMVASTATIN Atherosclerosis Supplements. 10: e800. DOI: 10.1016/S1567-5688(09)70782-2 |
0.444 |
|
| 2009 |
Hu M, Mak V, Poon E, Chu T, Tsui T, Tomlinson B. Abstract: P486 GENETIC DETERMINANTS OF LIPID RESPONSE TO ROSUVASTATIN IN CHINESE PATIENTS WITH HYPERCHOLESTEROLAEMIA Atherosclerosis Supplements. 10: e799. DOI: 10.1016/S1567-5688(09)70781-0 |
0.421 |
|
| 2009 |
Tomlinson B, Hu M, Mak V, Chu T, Lee V. Abstract: 36 EFFECTS OF GENETIC VARIANTS IN DRUG METABOLIZING ENZYMES AND TRANSPORTERS ON STATIN SAFETY AND EFFICACY Atherosclerosis Supplements. 10: e19. DOI: 10.1016/S1567-5688(09)70026-1 |
0.41 |
|
| 2008 |
Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Therapeutics and Clinical Risk Management. 4: 1209-20. PMID 19337428 DOI: 10.2147/Tcrm.S3310 |
0.464 |
|
| 2008 |
Tomlinson B, Hu M, Lee VW. In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? Molecular Nutrition & Food Research. 52: 799-809. PMID 18618477 DOI: 10.1002/Mnfr.200700454 |
0.478 |
|
| 2008 |
Tomlinson B, Mak V, Hu M, Yin O, Chow M. EFFECTS OF EFFLUX TRANSPORTER BCRP C421A POLYMORPHISM ON PITAVASTATIN PHARMACOKINETICS AND INTERACTION WITH GRAPEFRUIT JUICE Atherosclerosis Supplements. 9: 243. DOI: 10.1016/S1567-5688(08)70975-9 |
0.369 |
|
| 2008 |
Hu M, Tomlinson B, Lui S, Ko G. COMPARISON OF THE EFFICACY AND SAFETY OF ROSUVASTATIN WITH ATORVASTATIN FOR ACHIEVING LIPID GOALS: THE DISCOVERY- HONG KONG STUDY Atherosclerosis Supplements. 9: 199. DOI: 10.1016/S1567-5688(08)70796-7 |
0.391 |
|
| 2008 |
Mak V, Hu M, Yin O, Chow M, Tomlinson B. P327 Interaction of pitavastatin with grapefruit juice in subjects with different efflux transporter BCRP ABCG2 421C>A genotypes International Journal of Cardiology. 125: S59. DOI: 10.1016/S0167-5273(08)70238-9 |
0.382 |
|
| 2008 |
Hu M, Tomlinson B, Lui S, Chu T, Poon E, Baum L, Lee V. O105 Pharmacogenetics of lipid responses to rosuvastatin in Chinese patients: effects of polymorphisms in BCRP and CYP2D6 International Journal of Cardiology. 125: S41. DOI: 10.1016/S0167-5273(08)70182-7 |
0.5 |
|
| Show low-probability matches. |